Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

Abstract Background The most common biomarkers of Alzheimer’s disease (AD) are amyloid β (Aβ) and tau, detected in cerebrospinal fluid (CSF) or with positron emission tomography imaging. However, these procedures are invasive and expensive, which hamper their availability to the general population....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Longfei Jia, Min Zhu, Jianwei Yang, Yana Pang, Qi Wang, Ying Li, Tingting Li, Fangyu Li, Qigeng Wang, Yan Li, Yiping Wei
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Alzheimer’s disease Dementia MicroRNA Biomarker Diagnosis Medicine R
Acceso en línea:	https://doaj.org/article/1a5ed875f62646dea79fa1c3a91d7bad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a5ed875f62646dea79fa1c3a91d7bad
record_format	dspace
spelling	oai:doaj.org-article:1a5ed875f62646dea79fa1c3a91d7bad2021-11-21T12:16:09ZPrediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease10.1186/s12916-021-02142-x1741-7015https://doaj.org/article/1a5ed875f62646dea79fa1c3a91d7bad2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12916-021-02142-xhttps://doaj.org/toc/1741-7015Abstract Background The most common biomarkers of Alzheimer’s disease (AD) are amyloid β (Aβ) and tau, detected in cerebrospinal fluid (CSF) or with positron emission tomography imaging. However, these procedures are invasive and expensive, which hamper their availability to the general population. Here, we report a panel of microRNAs (miRNAs) in serum that can predict P-tau/Aβ42 in CSF and readily differentiate AD from other dementias, including vascular dementia (VaD), Parkinson disease dementia (PDD), behavioral variant frontotemporal dementia (bvFTD), and dementia with Lewy body (DLB). Methods RNA samples were extracted from the participant’s blood. P-tau/Aβ42 of CSF was examined for diagnostic purposes. A pilot study (controls, 21; AD, 23), followed by second (controls, 216; AD, 190) and third groups (controls, 153; AD, 151), is used to establish and verify a predictive model of P-tau/Aβ42 in CSF. The test is then applied to a fourth group of patients with different dementias (controls, 139; AD,155; amnestic mild cognitive impairment [aMCI], 55; VaD, 51; PDD, 53; bvFTD, 53; DLB, 52) to assess its diagnostic capacity. Results In the pilot study, 29 upregulated and 31 downregulated miRNAs in the AD group were found. In Dataset 2, these miRNAs were then included as independent variables in the linear regression model. A seven-microRNA panel (miR-139-3p, miR-143-3p, miR-146a-5p, miR-485-5p, miR-10a-5P, miR-26b-5p, and miR-451a-5p) accurately predicted values of P-tau/Aβ42 of CSF. In Datasets 3 and 4, by applying the predicted P-tau/Aβ42, the predictive model successfully differentiates AD from controls and VaD, PDD, bvFTD, and DLB. Conclusions This study suggests that the panel of microRNAs is a promising substitute for traditional measurement of P-tau/Aβ42 in CSF as an effective biomarker of AD.Longfei JiaMin ZhuJianwei YangYana PangQi WangYing LiTingting LiFangyu LiQigeng WangYan LiYiping WeiBMCarticleAlzheimer’s diseaseDementiaMicroRNABiomarkerDiagnosisMedicineRENBMC Medicine, Vol 19, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Alzheimer’s disease Dementia MicroRNA Biomarker Diagnosis Medicine R
spellingShingle	Alzheimer’s disease Dementia MicroRNA Biomarker Diagnosis Medicine R Longfei Jia Min Zhu Jianwei Yang Yana Pang Qi Wang Ying Li Tingting Li Fangyu Li Qigeng Wang Yan Li Yiping Wei Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
description	Abstract Background The most common biomarkers of Alzheimer’s disease (AD) are amyloid β (Aβ) and tau, detected in cerebrospinal fluid (CSF) or with positron emission tomography imaging. However, these procedures are invasive and expensive, which hamper their availability to the general population. Here, we report a panel of microRNAs (miRNAs) in serum that can predict P-tau/Aβ42 in CSF and readily differentiate AD from other dementias, including vascular dementia (VaD), Parkinson disease dementia (PDD), behavioral variant frontotemporal dementia (bvFTD), and dementia with Lewy body (DLB). Methods RNA samples were extracted from the participant’s blood. P-tau/Aβ42 of CSF was examined for diagnostic purposes. A pilot study (controls, 21; AD, 23), followed by second (controls, 216; AD, 190) and third groups (controls, 153; AD, 151), is used to establish and verify a predictive model of P-tau/Aβ42 in CSF. The test is then applied to a fourth group of patients with different dementias (controls, 139; AD,155; amnestic mild cognitive impairment [aMCI], 55; VaD, 51; PDD, 53; bvFTD, 53; DLB, 52) to assess its diagnostic capacity. Results In the pilot study, 29 upregulated and 31 downregulated miRNAs in the AD group were found. In Dataset 2, these miRNAs were then included as independent variables in the linear regression model. A seven-microRNA panel (miR-139-3p, miR-143-3p, miR-146a-5p, miR-485-5p, miR-10a-5P, miR-26b-5p, and miR-451a-5p) accurately predicted values of P-tau/Aβ42 of CSF. In Datasets 3 and 4, by applying the predicted P-tau/Aβ42, the predictive model successfully differentiates AD from controls and VaD, PDD, bvFTD, and DLB. Conclusions This study suggests that the panel of microRNAs is a promising substitute for traditional measurement of P-tau/Aβ42 in CSF as an effective biomarker of AD.
format	article
author	Longfei Jia Min Zhu Jianwei Yang Yana Pang Qi Wang Ying Li Tingting Li Fangyu Li Qigeng Wang Yan Li Yiping Wei
author_facet	Longfei Jia Min Zhu Jianwei Yang Yana Pang Qi Wang Ying Li Tingting Li Fangyu Li Qigeng Wang Yan Li Yiping Wei
author_sort	Longfei Jia
title	Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
title_short	Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
title_full	Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
title_fullStr	Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
title_full_unstemmed	Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
title_sort	prediction of p-tau/aβ42 in the cerebrospinal fluid with blood micrornas in alzheimer’s disease
publisher	BMC
publishDate	2021
url	https://doaj.org/article/1a5ed875f62646dea79fa1c3a91d7bad
work_keys_str_mv	AT longfeijia predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT minzhu predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT jianweiyang predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT yanapang predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT qiwang predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT yingli predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT tingtingli predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT fangyuli predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT qigengwang predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT yanli predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease AT yipingwei predictionofptauab42inthecerebrospinalfluidwithbloodmicrornasinalzheimersdisease
_version_	1718419110563414016

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

Ejemplares similares